Recursion Pharmaceuticals (RXRX) Competitor Comparison
We are evaluating the key criteria listed to compare Recursion Pharmaceuticals (RXRX) against its competitors in the Biotechnology industry.
Market Capitalization
54 / 368Gross Profits
258 / 278Total Revenue
127 / 300EBITDA
300 / 337Free Cashflow
306 / 352Quick Ratio
211 / 357Earnings per Share
178 / 359Dividend yield
0 / 6Total Cash
78 / 358Performance 3 years
198 / 368Performance 5 years
227 / 368Performance 10 years
196 / 368Linearity 3 years
140 / 368Linearity 5 years
242 / 368Linearity 10 years
204 / 367Total Rank
244 / 368Dividend Rank
257 / 368Valuation Rank
25 / 368Piotroski Rank
91 / 368Muliplier Rank
190 / 368Market Capitalization - RXRX ranking 54 / 368
Obligatory risk notice
We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.